AASLD 2012 Eric Lawitz from Alamo Medical Research, Texas © Liz Highleyman / hivandhepatitis.comManaging anaemiaStrategies for people taking boceprevir. Kris Kowdley, Liver Center of Excellence at Virginia Mason Medical Center, Seattle © Liz Highleyman / hivandhepatitis.com"Promising" resultsResearch into interferon-free combination. Mark Sulkowski from Johns Hopkins University School of Medicine. © Liz Highleyman / hivandhepatitis.com HIV and HCV co-infectionTelaprevir study results. infohep news Hepatitis B Adding pegylated interferon to entecavir improves hepatitis B treatment response Liz Highleyman / 13 December 2012 Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a presentation at The ... Treatment issues Adherence to hepatitis C treatment: unravelling the complexities Rob Camp / 13 December 2012 Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ... Therapies Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients? Liz Highleyman / 12 December 2012 An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot ... Treatment for previous non-responders & relapsers Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Hepatocellular carcinoma (HCC) Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising Liz Highleyman / 05 December 2012 The investigational cancer drug brivanib did not significantly increase survival for people with hepatocellular carcinoma over existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ... Therapies Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon Liz Highleyman / 03 December 2012 An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C patients, according to findings from ... Hepatitis B Nucleoside analogues reduce hepatitis B liver cancer risk Liz Highleyman / 29 November 2012 Treatment of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection surgery, according to data presented ... Treatment issues Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis Liz Highleyman / 23 November 2012 The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved three-times-daily schedule, with similar safety ... Treatment issues Which patients should be prioritised for new hepatitis C treatments? Rob Camp / 23 November 2012 Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ... Deciding when and how to treat HCV Low viral load in hepatitis C treatment: Is a third drug necessary? Rob Camp / 23 November 2012 When resources for hepatitis C treatment with new directly acting antivirals are limited, findings from the United States suggest that previously untreated people with low viral loads may stand a good chance ... View more > Editors' picks from other sources Therapies Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study HCV New Drugs Research / 14 November 2012 Therapies Gilead May Top Rivals With Hepatitis C Therapy Results Bloomberg BusinessWeek / 14 November 2012 Interferon-free regimens Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations Abbott press release / 14 November 2012 Background liver proliferation linked to noncirrhotic HCC in patients with HCV Healio Hepatology / 13 November 2012 Therapies Achillion Provides Update on Clinical HCV Development Programs Achillion press release / 13 November 2012 Therapies Novartis' Certican succeeds in liver transplant trial Reuters / 12 November 2012 AASLD-GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients HCV New Drugs Research / 12 November 2012 Therapies Gilead, Abbott Unwrap Dueling Hep C Pill Data The Street / 12 November 2012 Therapies ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C Vertex press release / 11 November 2012 Therapies Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily Vertex press release / 11 November 2012 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive